Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med. 2020; 383: 1413-1424
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2021; 385: 1451-1461
- Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction.Can J Cardiol. 2022; 38: 1641-1642
- Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction.Int Heart J. 2022; 63: 852-856
Publication stageIn Press Journal Pre-Proof
Funding Sources: None.
Disclosures: The authors had no conflicts of interest to disclose.